Boehringer Ingelheim International GmbH

General information
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein, Rhineland-Palatinate
Germany

Contact person: Sebastian Guntrum, Management Board
Company main phone: +49 (6132) 770
Company main fax:  +49 (6132) 720
Website:  https://www.boehringer-ingelheim.com
Year founded:1885
Source of foundation:Independent foundation
Name of foundation source:Founded by Mr. Albert Boehringer
No. of employees: Worldwide:  52000
Corporate description / mission:
Boehringer Ingelheim International GmbH researches, develops, manufactures and markets human and veterinary pharmaceutical products. The company's product Aptivus® indicated for combination antiretroviral treatment of HIV-1-infected patients, co-administered with 200 mg of ritonavir, who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor.
State of ownership: Private / independent
Headquarters: Yes
Remarks on ownership / listings
Boehringer Ingelheim GmbH was formerly known as Boehringer Ingelheim Zentrale GmbH and changed its name to Boehringer Ingelheim GmbH in 1989.
Categorization
Sector:
  • Pharma (fully integrated)
Subsector:
  • Anti-infectives
  • Antibodies
  • Nucleic acid drugs
  • Peptides
  • Proteins
  • Vaccines
Primary therapeutic areas:
  • Cardiovascular / cardiology
  • Digestive system / gastroenterology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Diseases of the nervous system / neurology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Mental and behavioural disorders / psychiatry /psychology
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
Business model:
  • Manufacturer
  • R&D
  • Supplier / Distributor
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
  • Small biotech
Distribution:
  • Direct (own sales force)
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:4
Phase I:29
Phase II:16
Phase III:6
On the market:6
Description of products:
Empagliflozin
Spesolimab (BI 655130)
BI 685509, etc.
Collaborations & Clients
Partnering strategy / collaborations:
Institute of Molecular Pathology (IMP)
Institute of Molecular Biology (IMB)
University of Applied Sciences in Biberach, Germany
University of Ulm, Germany
Technische Universität Dresden, etc.
X